Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.
Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS, Henry C, Woods A, Ma L, Stewart-Jones GB, Bock KW, Minai M, Nagata BM, Periasamy S, Shi PY, Graham BS, Moore IN, Ramos I, Troyanskaya OG, Zaslavsky E, Carfi A, Sealfon SC, Bukreyev A. Meyer M, et al. Among authors: periasamy s. J Clin Invest. 2021 Oct 15;131(20):e148036. doi: 10.1172/JCI148036. J Clin Invest. 2021. PMID: 34449440 Free PMC article.
mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge.
Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS, Henry C, Woods A, Ma L, Stewart-Jones GBE, Bock KW, Minai M, Nagata BM, Periasamy S, Shi PY, Graham BS, Moore IN, Ramos I, Troyanskaya OG, Zaslavsky E, Carfi A, Sealfon SC, Bukreyev A. Meyer M, et al. Among authors: periasamy s. bioRxiv [Preprint]. 2021 Jan 25:2021.01.25.428136. doi: 10.1101/2021.01.25.428136. bioRxiv. 2021. PMID: 33532780 Free PMC article. Updated. Preprint.
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2.
Ilinykh PA, Periasamy S, Huang K, Kuzmina NA, Ramanathan P, Meyer MN, Mire CE, Kuzmin IV, Bharaj P, Endsley JR, Chikina M, Sealfon SC, Widen SG, Endsley MA, Bukreyev A. Ilinykh PA, et al. Among authors: periasamy s. NPJ Vaccines. 2022 Apr 25;7(1):47. doi: 10.1038/s41541-022-00471-3. NPJ Vaccines. 2022. PMID: 35468973 Free PMC article.
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.
Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, Kalveram B, Bukreyev A, Ren P, Wang T, Menachery VD, Plante KS, Xie X, Weaver SC, Shi PY. Liu Y, et al. Among authors: periasamy s. Nat Commun. 2022 Jul 27;13(1):4337. doi: 10.1038/s41467-022-31930-z. Nat Commun. 2022. PMID: 35896528 Free PMC article.
Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19.
Soares-Schanoski A, Sauerwald N, Goforth CW, Periasamy S, Weir DL, Lizewski S, Lizewski R, Ge Y, Kuzmina NA, Nair VD, Vangeti S, Marjanovic N, Cappuccio A, Cheng WS, Mofsowitz S, Miller CM, Yu XB, George MC, Zaslavsky E, Bukreyev A, Troyanskaya OG, Sealfon SC, Letizia AG, Ramos I. Soares-Schanoski A, et al. Among authors: periasamy s. Front Immunol. 2022 Apr 5;13:821730. doi: 10.3389/fimmu.2022.821730. eCollection 2022. Front Immunol. 2022. PMID: 35479098 Free PMC article.
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
Malherbe DC, Kurup D, Wirblich C, Ronk AJ, Mire C, Kuzmina N, Shaik N, Periasamy S, Hyde MA, Williams JM, Shi PY, Schnell MJ, Bukreyev A. Malherbe DC, et al. Among authors: periasamy s. NPJ Vaccines. 2021 Jul 22;6(1):91. doi: 10.1038/s41541-021-00352-1. NPJ Vaccines. 2021. PMID: 34294728 Free PMC article.
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
Shiakolas AR, Kramer KJ, Johnson NV, Wall SC, Suryadevara N, Wrapp D, Periasamy S, Pilewski KA, Raju N, Nargi R, Sutton RE, Walker LM, Setliff I, Crowe JE Jr, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Shiakolas AR, et al. Among authors: periasamy s. Nat Biotechnol. 2022 Aug;40(8):1270-1275. doi: 10.1038/s41587-022-01232-2. Epub 2022 Mar 3. Nat Biotechnol. 2022. PMID: 35241839 Free PMC article.
Publisher Correction: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.
Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, Kalveram B, Bukreyev A, Ren P, Wang T, Menachery VD, Plante KS, Xie X, Weaver SC, Shi PY. Liu Y, et al. Among authors: periasamy s. Nat Commun. 2022 Oct 13;13(1):6060. doi: 10.1038/s41467-022-33878-6. Nat Commun. 2022. PMID: 36229471 Free PMC article. No abstract available.
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.
Lake DF, Roeder AJ, Kaleta E, Jasbi P, Pfeffer K, Koelbela C, Periasamy S, Kuzmina N, Bukreyev A, Grys TE, Wu L, Mills JR, McAulay K, Gonzalez-Moa M, Seit-Nebi A, Svarovsky S. Lake DF, et al. Among authors: periasamy s. J Clin Virol. 2021 Dec;145:105024. doi: 10.1016/j.jcv.2021.105024. Epub 2021 Nov 4. J Clin Virol. 2021. PMID: 34781240 Free PMC article.
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
Kramer KJ, Johnson NV, Shiakolas AR, Suryadevara N, Periasamy S, Raju N, Williams JK, Wrapp D, Zost SJ, Walker LM, Wall SC, Holt CM, Hsieh CL, Sutton RE, Paulo A, Nargi RS, Davidson E, Doranz BJ, Crowe JE Jr, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Kramer KJ, et al. Among authors: periasamy s. Cell Rep. 2021 Oct 5;37(1):109784. doi: 10.1016/j.celrep.2021.109784. Epub 2021 Sep 16. Cell Rep. 2021. PMID: 34592170 Free PMC article.
149 results